Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Publication date
2019-11
Authors
Mastellos, Dimitrios C
Blom, Anna M
Connolly, E Sander
Daha, Mohamed R
Geisbrecht, Brian V
Ghebrehiwet, Berhane
Gros, P.
Hajishengallis, George
Holers, V Michael
Huber-Lang, Markus
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
No license information available
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Keywords
Taverne
Citation
Mastellos, D C, Blom, A M, Connolly, E S, Daha, M R, Geisbrecht, B V, Ghebrehiwet, B, Gros, P, Hajishengallis, G, Holers, V M, Huber-Lang, M, Kinoshita, T, Mollnes, T E, Montgomery, R A, Morgan, B P, Nilsson, B, Pio, R, Ricklin, D, Risitano, A M, Taylor, R P, Mantovani, A, Ioannidis, J P A & Lambris, J D 2019, 'Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development', Nature Immunology, vol. 20, no. 11, 1556. https://doi.org/10.1038/s41590-019-0531-x